June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...

Please provide your email address to receive an email when new articles are posted on . According to Kuppermann, Steinert Endowed Professor and chair of the department of ophthalmology and visual ...

An intravitreal implant (OTX-TKI) containing the tyrosine kinase inhibitor axitinib (Inlyta) was well tolerated and significantly reduced injection frequency by nearly 90% in patients with wet ...

Intravitreal dexamethasone implants stabilized, but did not improve, vision for most patients with macular edema due to retinal vein occlusion (RVO). Intravitreal dexamethasone implants were found to ...

Outcomes for patients with diabetic macular edema did not have treatment with intravitreal dexamethasone implants affected by their glycosylated hemoglobin. Patients who have diabetic macular edema ...

This appraisal focuses only on the partial review for people who have a phakic (natural) lens. Considerations for people with a pseudophakic (intraocular) lens are still available in the evidence ...

Review the side-effects of Dexamethasone Intravitreal Implant as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the ...

Learn everything you need to know about Dexamethasone Intravitreal Implant-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects ...

1.1 Dexamethasone intravitreal implant is recommended as an option for treating visual impairment caused by diabetic macular oedema in adults only if their condition has not responded well enough to, ...